Literature DB >> 21680520

Role of TRIM5α RING domain E3 ubiquitin ligase activity in capsid disassembly, reverse transcription blockade, and restriction of simian immunodeficiency virus.

Jonghwa Kim1, Christopher Tipper, Joseph Sodroski.   

Abstract

The mammalian tripartite motif protein, TRIM5α, recognizes retroviral capsids entering the cytoplasm and blocks virus infection. Depending on the particular TRIM5α protein and retrovirus, complete disruption of the TRIM5α RING domain decreases virus-restricting activity to various degrees. TRIM5α exhibits RING domain-dependent E3 ubiquitin ligase activity, but the specific role of this activity in viral restriction is unknown. We created a panel of African green monkey TRIM5α (TRIM5α(AGM)) mutants, many of which are specifically altered in RING domain E3 ubiquitin ligase function, and characterized the phenotypes of these mutants with respect to restriction of simian and human immunodeficiency viruses (SIV(mac) and HIV-1, respectively). TRIM5α(AGM) ubiquitin ligase activity was essential for both the accelerated disassembly of SIV(mac) capsids and the disruption of reverse transcription. The levels of SIV(mac) particulate capsids in the cytosol of target cells expressing the TRIM5α variants strongly correlated with the levels of viral late reverse transcripts. RING-mediated ubiquitylation and B30.2(SPRY) domain-determined capsid binding independently contributed to the potency of SIV(mac) restriction by TRIM5α(AGM). In contrast, TRIM5α proteins attenuated in RING ubiquitin ligase function still accelerated HIV-1 capsid disassembly, inhibited reverse transcription, and blocked infection. Replacement of the helix-4/5 loop in the SIV(mac) capsid with the corresponding region of the HIV-1 capsid diminished the dependence of restriction on TRIM5α RING function. Thus, ubiquitylation mediated by the RING domain of TRIM5α(AGM) is essential for blocking SIV(mac) infection at the stage of capsid uncoating.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21680520      PMCID: PMC3147946          DOI: 10.1128/JVI.00341-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  94 in total

1.  Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins.

Authors:  Jenny L Anderson; Edward M Campbell; Xiaolu Wu; Nick Vandegraaff; Alan Engelman; Thomas J Hope
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  Capsid stability and replication of human immunodeficiency virus type 1 are influenced critically by charge and size of Gag residue 183.

Authors:  Bernd Leschonsky; Christine Ludwig; Kurt Bieler; Ralf Wagner
Journal:  J Gen Virol       Date:  2007-01       Impact factor: 3.891

3.  Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp.

Authors:  Felipe Diaz-Griffero; Alak Kar; Mark Lee; Matthew Stremlau; Eric Poeschla; Joseph Sodroski
Journal:  Virology       Date:  2007-10-24       Impact factor: 3.616

4.  Antiretroviral potential of human tripartite motif-5 and related proteins.

Authors:  Fengwen Zhang; Theodora Hatziioannou; David Perez-Caballero; David Derse; Paul D Bieniasz
Journal:  Virology       Date:  2006-07-10       Impact factor: 3.616

5.  TRIMCyp expression in Old World primates Macaca nemestrina and Macaca fascicularis.

Authors:  Greg Brennan; Yury Kozyrev; Shiu-Lok Hu
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

6.  Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species.

Authors:  Cesar A Virgen; Zerina Kratovac; Paul D Bieniasz; Theodora Hatziioannou
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

7.  Novel TRIM5 isoforms expressed by Macaca nemestrina.

Authors:  Greg Brennan; Yury Kozyrev; Toshiaki Kodama; Shiu-Lok Hu
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

8.  A novel fusion gene, TRIM5-Cyclophilin A in the pig-tailed macaque determines its susceptibility to HIV-1 infection.

Authors:  Cheng-Hong Liao; Yi-Qun Kuang; Hong-Liang Liu; Yong-Tang Zheng; Bing Su
Journal:  AIDS       Date:  2007-12       Impact factor: 4.177

9.  SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells.

Authors:  Caroline Goujon; Lise Rivière; Loraine Jarrosson-Wuilleme; Jeanine Bernaud; Dominique Rigal; Jean-Luc Darlix; Andrea Cimarelli
Journal:  Retrovirology       Date:  2007-01-09       Impact factor: 4.602

10.  Cyclophilin A interacts with diverse lentiviral capsids.

Authors:  Tsai-Yu Lin; Michael Emerman
Journal:  Retrovirology       Date:  2006-10-12       Impact factor: 4.602

View more
  23 in total

1.  RING domain mutations uncouple TRIM5α restriction of HIV-1 from inhibition of reverse transcription and acceleration of uncoating.

Authors:  Amanda Roa; Fumiaki Hayashi; Yang Yang; Maritza Lienlaf; Jing Zhou; Jiong Shi; Satoru Watanabe; Takanori Kigawa; Shigeyuki Yokoyama; Christopher Aiken; Felipe Diaz-Griffero
Journal:  J Virol       Date:  2011-11-23       Impact factor: 5.103

2.  General Model for Retroviral Capsid Pattern Recognition by TRIM5 Proteins.

Authors:  Jonathan M Wagner; Devin E Christensen; Akash Bhattacharya; Daria M Dawidziak; Marcin D Roganowicz; Yueping Wan; Ruth A Pumroy; Borries Demeler; Dmitri N Ivanov; Barbie K Ganser-Pornillos; Wesley I Sundquist; Owen Pornillos
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

3.  Recruitment and dynamics of proteasome association with rhTRIM5α cytoplasmic complexes during HIV-1 infection.

Authors:  Cindy M Danielson; Gianguido C Cianci; Thomas J Hope
Journal:  Traffic       Date:  2012-06-19       Impact factor: 6.215

4.  Centrosomal protein TRIM43 restricts herpesvirus infection by regulating nuclear lamina integrity.

Authors:  Florian Full; Michiel van Gent; Konstantin M J Sparrer; Cindy Chiang; Matthew A Zurenski; Myriam Scherer; Norbert H Brockmeyer; Lucie Heinzerling; Michael Stürzl; Klaus Korn; Thomas Stamminger; Armin Ensser; Michaela U Gack
Journal:  Nat Microbiol       Date:  2018-11-12       Impact factor: 17.745

5.  Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to human TRIM5alpha, linking intrinsic and acquired immunity.

Authors:  Emilie Battivelli; Julie Migraine; Denise Lecossier; Patrick Yeni; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

6.  Binding of the rhesus TRIM5α PRYSPRY domain to capsid is necessary but not sufficient for HIV-1 restriction.

Authors:  Yang Yang; Alberto Brandariz-Nuñez; Thomas Fricke; Dmitri N Ivanov; Zoe Sarnak; Felipe Diaz-Griffero
Journal:  Virology       Date:  2013-10-31       Impact factor: 3.616

7.  Contribution of glutamine residues in the helix 4-5 loop to capsid-capsid interactions in simian immunodeficiency virus of macaques.

Authors:  Christopher Tipper; Joseph G Sodroski
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

8.  RING Dimerization Links Higher-Order Assembly of TRIM5α to Synthesis of K63-Linked Polyubiquitin.

Authors:  Zinaida Yudina; Amanda Roa; Rory Johnson; Nikolaos Biris; Daniel A de Souza Aranha Vieira; Vladislav Tsiperson; Natalia Reszka; Alexander B Taylor; P John Hart; Borries Demeler; Felipe Diaz-Griffero; Dmitri N Ivanov
Journal:  Cell Rep       Date:  2015-07-23       Impact factor: 9.423

9.  Pressure from TRIM5α contributes to control of HIV-1 replication by individuals expressing protective HLA-B alleles.

Authors:  Clémence Granier; Emilie Battivelli; Camille Lécuroux; Alain Venet; Olivier Lambotte; Marion Schmitt-Boulanger; Constance Delaugerre; Jean-Michel Molina; Lisa A Chakrabarti; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

10.  Rhesus monkey TRIM5α protein SPRY domain contributes to AP-1 activation.

Authors:  Lei Na; Yan-Dong Tang; Cuihui Wang; Cong Liu; Xiaojun Wang
Journal:  J Biol Chem       Date:  2017-12-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.